Compounds > way 163909
Page last updated: 2024-11-12

way 163909

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID10130594
CHEMBL ID1628670
SCHEMBL ID4352287
MeSH IDM0486440

Synonyms (24)

Synonym
way-163909
bdbm50076245
chembl1628670 ,
(11r,15r)-7,10-diazatetracyclo[8.5.1.0^{5,16}.0^{11,15}]hexadeca-1,3,5(16)-triene
gtpl229
SCHEMBL4352287
way163909
way 163909
AKOS016004084
428868-32-0
(7br,10ar)-2,3,4,7b,8,9,10,10a-octahydro-1h-cyclopenta[b][1,4]diazepino[6,7,1-hi]indole
DTXSID40436021
(7br,10ar)-1,2,3,4,8,9,10,10a-octahydro-7bh-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole
CS-0006248
HY-15401
Q27089215
unii-mn9lw8268n
(7br,10ar)-1,2,3,4,7a,9,10,10a-octahydro-8h-cyclopenta(4,5)pyrrolo(3,2,1-jk)(1,4)benzodiazepine
(7br,10ar)-2,3,4,7b,8,9,10,10a-octahydro-1h-cyclopenta(b)(1,4)diazepino(6,7,1-hi)indole
way-163,909
MN9LW8268N ,
8h-cyclopenta(4,5)pyrrolo(3,2,1-jk)(1,4)benzodiazepine, 1,2,3,4,7a,9,10,10a-octahydro-, (7br,10ar)-
(7br,10ar)-1,2,3,4,7b,9,10,10a-octahydro-8h-cyclopenta[b][1,4]diazepino[6,7,1-hi]indole
(11r,15r)-7,10-diazatetracyclo[8.5.1.05,16.011,15]hexadeca-1,3,5(16)-triene
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki0.01020.00010.954910.0000AID1075710; AID1656823
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 2CHomo sapiens (human)EC50 (µMol)0.00800.00010.10082.4500AID1075711; AID1199723
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 2CHomo sapiens (human)K0.00900.00300.00730.0100AID1855127; AID1855128
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (19)

Processvia Protein(s)Taxonomy
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID1664075Neurobiological activity in Sprague-Dawley rat assessed as increase in number of rat choosing drug associated lever at 0.5 mg/kg, ip treated 15 mins prior to test by drug discrimination test relative to control2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Discovery of 4-Phenylpiperidine-2-Carboxamide Analogues as Serotonin 5-HT
AID1664070Neurobiological activity in Sprague-Dawley rat assessed as increase in number of rat choosing drug associated lever at 0.75 mg/kg, ip treated 15 mins prior to test by drug discrimination test relative to control2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Discovery of 4-Phenylpiperidine-2-Carboxamide Analogues as Serotonin 5-HT
AID1664067Neurobiological activity in Sprague-Dawley rat assessed as increase in number of rat choosing drug associated lever by measuring response rate half life at 0.75 mg/kg, ip treated 15 mins prior to test by drug discrimination test2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Discovery of 4-Phenylpiperidine-2-Carboxamide Analogues as Serotonin 5-HT
AID1656823Binding affinity to 5HT2C receptor (unknown origin)2020Bioorganic & medicinal chemistry letters, 03-01, Volume: 30, Issue:5
Discovery of a lead series of potent benzodiazepine 5-HT
AID1199723Agonist activity at 5HT2C receptor (unknown origin) relative to control2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.
AID1664069Neurobiological activity in ip dosed Sprague-Dawley rat assessed as increase in number of rat choosing drug associated lever treated 15 mins prior to test by drug discrimination test2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Discovery of 4-Phenylpiperidine-2-Carboxamide Analogues as Serotonin 5-HT
AID1656877Selectivity index, ratio of Ki for binding affinity to 5HT2A (unknown origin) to Ki for binding affinity to 5HT2C (unknown origin)2020Bioorganic & medicinal chemistry letters, 03-01, Volume: 30, Issue:5
Discovery of a lead series of potent benzodiazepine 5-HT
AID1664068Neurobiological activity in Sprague-Dawley rat assessed as increase in number of rat choosing drug associated lever by measuring response rate half life at 1 mg/kg, ip treated 15 mins prior to test by drug discrimination test2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Discovery of 4-Phenylpiperidine-2-Carboxamide Analogues as Serotonin 5-HT
AID1075711Agonist activity at human 5-HT2C receptor assessed as stimulation of Ca2+ mobilization2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Imaging evaluation of 5HT2C agonists, [(11)C]WAY-163909 and [(11)C]vabicaserin, formed by Pictet-Spengler cyclization.
AID1075710Displacement of [125I]DOI from human 5-HT2C receptor2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Imaging evaluation of 5HT2C agonists, [(11)C]WAY-163909 and [(11)C]vabicaserin, formed by Pictet-Spengler cyclization.
AID1855127Binding affinity to 5-HT2C (unknown origin)2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Positron Emission Tomography (PET) Imaging Tracers for Serotonin Receptors.
AID1199724Agonist activity at 5HT2B receptor (unknown origin) relative to control2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.
AID1664074Neurobiological activity in Sprague-Dawley rat assessed as increase in number of rat choosing drug associated lever at 0.25 to 0.625 mg/kg, ip treated 15 mins prior to test by drug discrimination test2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Discovery of 4-Phenylpiperidine-2-Carboxamide Analogues as Serotonin 5-HT
AID1664076Neurobiological activity in Sprague-Dawley rat assessed as increase in number of rat choosing drug associated lever at 0.625 mg/kg, ip treated 15 mins prior to test by drug discrimination test relative to control2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Discovery of 4-Phenylpiperidine-2-Carboxamide Analogues as Serotonin 5-HT
AID1855128Agonist activity at 5-HT2C receptor (unknown origin)2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Positron Emission Tomography (PET) Imaging Tracers for Serotonin Receptors.
AID1664073Neurobiological activity in Sprague-Dawley rat assessed as increase in number of rat choosing drug associated lever at 1 mg/kg, ip treated 15 mins prior to test by drug discrimination test relative to control2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Discovery of 4-Phenylpiperidine-2-Carboxamide Analogues as Serotonin 5-HT
AID1656882Selectivity index, ratio of Ki for binding affinity to 5HT2B (unknown origin) to Ki for binding affinity to 5HT2C (unknown origin)2020Bioorganic & medicinal chemistry letters, 03-01, Volume: 30, Issue:5
Discovery of a lead series of potent benzodiazepine 5-HT
AID1346893Human 5-HT2C receptor (5-Hydroxytryptamine receptors)2005The Journal of pharmacology and experimental therapeutics, May, Volume: 313, Issue:2
WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity.
AID624216Agonists at Human 5-Hydroxytryptamine receptor 5-HT2C2005The Journal of pharmacology and experimental therapeutics, May, Volume: 313, Issue:2
WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's2 (33.33)24.3611
2020's3 (50.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.18 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index5.12 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
8-hydroxy-2-(di-n-propylamino)tetralin
8-Hydroxy-2-(di-n-propylamino)tetralin: A serotonin 1A-receptor agonist that is used experimentally to test the effects of serotonin.. 8-OH-DPAT : A tetralin substituted at positions 1 and 7 by hydroxy and dipropylamino groups respectively		3.5110phenols;
tertiary amino compound;
tetralins		serotonergic antagonist
ketanserin
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.. ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.		3.5110aromatic ketone;
organofluorine compound;
piperidines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
cardiovascular drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
n-methylquipazine
N-methylquipazine: structure in first source. N-methylquipazine : An aminoquinoline that consists of quinoline in which the hydrogen at position 2 is substituted by a 4-methylpiperazin-1-yl group. A 5-HT3 agonist. Has almost the same affinity for 5-HT3 sites as quipazine but unlike the latter, does not bind to 5-HT1B sites.		3.5110aminoquinoline;
N-alkylpiperazine;
N-arylpiperazine		serotonergic agonist
ritanserin
Ritanserin: A selective and potent serotonin-2 antagonist that is effective in the treatment of a variety of syndromes related to anxiety and depression. The drug also improves the subjective quality of sleep and decreases portal pressure.. ritanserin : A thiazolopyrimidine that is 5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one which is substituted at position 7 by a methyl group and at position 6 by a 2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl group. A potent and long-acting seratonin (5-hydroxytryptamine, 5-HT) antagonist of the subtype 5-HT2 (Ki = 0.39 nM), it is used in the treatment of a variety of disorders including anxiety, depression and schizophrenia. It has little sedative action.		3.5110organofluorine compound;
piperidines;
thiazolopyrimidine		antidepressant;
antipsychotic agent;
anxiolytic drug;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
n-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-n-(2-pyridinyl)cyclohexanecarboxamide
[no description available]		3.5110piperazines
fananserin
fananserin: RN & structure given in first source		3.5110naphthalenes;
sulfonic acid derivative
setoperone
[no description available]		3.5110
3-n-methylspiperone
3-N-methylspiperone: (11(C))-labeled cpd used in positron tomography; dopamine agonist & dopamine receptor ligand; structure given in first source		3.5110aromatic ketone
8-(di-n-propylamino)-6,7,8,9-tetrahydro-3h-benz(e)indole-1-carbaldehyde
8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz(e)indole-1-carbaldehyde: RN refers to (+-)-isomer; structure given in first source		3.5110
rs 127445
2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine: a 5-HT(2B) receptor antagonist; structure in first source		3.5110
altanserin
altanserin: structure given in first source; a radioligand for PET studies of serotonin S2 receptors		3.5110quinazolines
ly 344864
LY 344864: has selective affinity for the 5-HT1F receptor; structure in first source		3.5110carbazoles
mdl 100907
Serotonin 5-HT2 Receptor Antagonists: Drugs that bind to but do not activate SEROTONIN 5-HT2 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT2 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more specific 5-HT2 receptor subtypes.		3.5110
s 21007
[no description available]		3.5110
f 13640
befiradol: a selective serotonin 5-HT1A receptor agonist		3.5110
2-(3-chlorobenzyloxy)-6-(piperazin-1-yl)pyrazine
[no description available]		2.1110
pimavanserin
pimavanserin: A 5-HT(2A) inverse agonist; ACP-103 is the dihydroxybutanedioate (2:1) salt. It is used to treat hallucinations and delusions associated with PARKINSON DISEASE; structure in first source.. pimavanserin : A member of the class of ureas in which three of the four hydrogens are replaced by 4-fluorobenzyl, 1-methylpiperidin-4-yl, and 4-(isopropyloxy)benzyl groups. An atypical antipsychotic that is used (in the form of its tartrate salt) for treatment of hallucinations and delusions associated with Parkinson's disease.		3.5110aromatic ether;
monofluorobenzenes;
piperidines;
tertiary amino compound;
ureas		5-hydroxytryptamine 2A receptor inverse agonist;
antipsychotic agent;
serotonergic antagonist
2-(4-iodo-2,5-dimethoxyphenyl)-n-(2-methoxybenzyl)ethanamine
2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine: a PET radioligand and 5-HT(2A) receptor agonist; also used as a designer drug; structure in first source		3.5110
1-(2,4-difluorophenethyl)-4-(4-fluorophenylsulfonyl)piperidine
1-(2,4-difluorophenethyl)-4-(4-fluorophenylsulfonyl)piperidine: a 5-HT2A receptor antagonist; structure in first source		3.5110
vabicaserin
vabicaserin: an antipsychotic agent and 5-HT2C receptor agonist; structure in first source		3.9430
col-144
lasmiditan: a high-affinity, highly selective serotonin 5-HT(1F) receptor agonist; structure in first source		3.5110
lorcaserin
lorcaserin: orally active, small-molecule 5-hydroxytryptamine 2C agonist for the potential treatment of obesity and diabetes. lorcaserin : A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine substituted at position 1 by a methyl group and a t position 6 by a chloro group.		2.5720benzazepine;
organochlorine compound		anti-obesity agent;
appetite depressant
e-55888
[no description available]		3.5110
ConditionIndicatedRelationship StrengthStudiesTrials